Key Highlights

  • Lycia Therapeutics (NASDAQ:LYCA) fell about 9.9% to near USD 27.05 in early trading on Monday, October 26, 2026, its second trading session after pricing an initial public offering at USD 18.00.
  • The offering of 17.64 million shares raised gross proceeds of about USD 317.5 million, with a 30-day option for the underwriters to buy up to 2,646,000 more shares.
  • The shares remain about 50% above the offer price, which implies a prior close near USD 30, so Lycia Therapeutics (NASDAQ:LYCA) is giving back part of a strong debut.
  • Lead programmes are LCA-0061, an IgE degrader for food allergy, and LCA-0321 for Graves disease, both built on the LYTAC platform.

A Pullback After a Strong Debut

Lycia Therapeutics (NASDAQ:LYCA) priced its upsized initial public offering on Thursday, October 22, 2026 at USD 18.00 per share, selling 17,640,000 shares for gross proceeds of about USD 317.5 million, with closing expected on Monday, October 26, 2026. Trading began on Friday, October 23, 2026 on the Nasdaq Global Select Market. The shares fell about 9.9% in early trading on Monday, October 26, 2026, with prices described as intraday near USD 27.05, which implies a prior close near USD 30. The company has not issued a release explaining the move, and profit taking after a first-day gain of this size is the usual pattern. Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities act as joint book-running managers.

How the Platform and Valuation Shape Trading

The mechanism is valuation against an early pipeline. Lycia Therapeutics (NASDAQ:LYCA) develops degraders, molecules that remove disease-causing proteins from outside the cell, using its LYTAC platform. LCA-0061, a degrader of immunoglobulin E for food allergy and other allergic diseases, and LCA-0321, designed to deplete the autoantibodies behind Graves disease, are the two lead candidates. With no approved product, the shares are priced on platform credibility and data expected from these programmes. A price near USD 27 is roughly 50% above the offer, so buyers at the offering now hold gains and some sell, while new buyers weigh the risk of clinical setbacks. The USD 317.5 million raise gives a long cash runway for a preclinical or early clinical company.

Risks and What to Watch

The first risk for Lycia Therapeutics (NASDAQ:LYCA) is volatility, since newly listed biotechnology shares often move 10% or more daily while the float is small and the underwriters' option remains open. The second is clinical, as early degrader programmes can fail on safety, dosing or efficacy. The third is supply: lock-up expiries, normally about 180 days after the offering, can release many shares, and the company has not announced the schedule. Investors should watch the first research initiations from the underwriters, which are customarily permitted 25 days after the offering, around Tuesday, November 17, 2026, the Federal Reserve decision on Wednesday, October 28, 2026 and the first quarterly report as a public company.

Where Things Stand

The answer is that Lycia Therapeutics (NASDAQ:LYCA) fell about 9.9% as early buyers took profits after a debut that left the shares about 50% above the USD 18.00 offer, and no company-specific negative news has been disclosed. The USD 317.5 million raise funds the IgE and Graves disease programmes. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, research initiations around Tuesday, November 17, 2026 and the first public quarterly results. Biotechnology shares are volatile, and this is not investment advice.